Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bicycle Therapeutics Plc ADR (NQ: BCYC )

20.38 +0.48 (+2.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 299,395
Open 20.34
Bid (Size) 19.46 (1)
Ask (Size) 21.36 (1)
Prev. Close 19.90
Today's Range 19.74 - 21.29
52wk Range 18.84 - 33.49
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023
Via Benzinga
Why Shares of Bicycle Therapeutics Were Rising on Monday
The company said it is working with the FDA to structure a phase 2/3 trial for its bladder cancer therapy. 
Via The Motley Fool
Exposures Product Safety

Performance

YTD
-32.07%
-32.07%
1 Month
-14.44%
-14.44%
3 Month
-17.82%
-17.82%
6 Month
-12.16%
-12.16%
1 Year
-10.42%
-10.42%

More News

Read More
Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer
From Bicycle Therapeutics
Via Business Wire
Where Bicycle Therapeutics Stands With Analysts
Via Benzinga
Expert Ratings for Bicycle Therapeutics
Via Benzinga
Bicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Bicycle Therapeutics
Via Business Wire
Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Non-Voting Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics's Return On Capital Employed Insights
Via Benzinga
Bicycle Therapeutics PLC (NASDAQ: BCYC) Making Surprising Moves in Friday Session
Via Investor Brand Network
14 Analysts Have This to Say About Bicycle Therapeutics
Via Benzinga
Recap: Bicycle Therapeutics Q1 Earnings
Via Benzinga
Why Bicycle Therapeutics Stock Raced Ahead Today
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Stratasys, MillerKnoll, Nikola And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Bicycle Therapeutics Announces Pricing of $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares
From Bicycle Therapeutics plc
Via Business Wire
Analyst Ratings for Bicycle Therapeutics
Via Benzinga
Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Appoints Alethia Young as Chief Financial Officer
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in the TD Cowen Radiopharmaceutical Innovation Summit
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics and Orano Med Present Preclinical Bicycle® Radio-Conjugate Data at TIDES 2023
From Bicycle Therapeutics plc
Via Business Wire
Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology
From Bayer
Via Business Wire
Bicycle Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle® Radio Conjugates for a Range of Oncology Targets
From Bicycle Therapeutics plc
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.